Pentraxin 3 as A Cardiovascular Marker in Primary Hyperparathyroidism
Journal Title: Journal of Endocrinology and Diabetes - Year 2018, Vol 5, Issue 4
Abstract
Aim: Pentraxin 3 (PTX3) is an acute-phase glycoprotein, which is increased in patients with cardiovascular disease (CVD) and considered as a predictor of CVD in the general population. Accumulating evidence suggests that even mild primary hyperparathyroidism (PHPT) has an elevated risk for CVD. We aimed to investigate plasma PTX3 levels before and after parathyroidectomy in patients with primary hyperparathyroidism and determine its relationship with cardiovascular risk factors Material and Method: Twenty-nine patients with PHPT and 26 healthy controls were enrolled in the study. Anthropometric and laboratory parameters were recorded both before and 6 months after parathyroidectomy. Serum PTX3 levels were measured using a human PTX3 enzyme-linked immunosorbent assay. Results: Plasma PTX3 concentrations were similar between before and after parathyroidectomy and control group (10.97 ± 16.0, 11.97 ± 11.49, 7.88 ± 9.48, respectively, p>0.05). Systolic blood pressure, diastolic blood pressure, carotid intima-media thickness (CIMT) and calcium, parathormone, fasting plasma glucose, alkaline phosphatase concentrations were higher in the PHPT group (p< 0.05). Creatinine and phosphorus concentrations were higher in the control group (p< 0.05). PTX3 was not correlated with cardi-metabolic risk factors except body mass index (BMI) (r2:0.414, p:0.0253). Conclusion: Plasma PTX3 was not increased as well was not changed after parathyroidectomy in patients with PHPT. The PTX3 was correlated with BMI; however, it was not associated with other cardio-metabolic risk factors including DBP, CIMT, and CRP. These findings might support PTX3 cannot be used as a cardio-metabolic risk marker in patients with PHPT.
Authors and Affiliations
Muhammed Kizilgul, Mustafa Calışkan, Ozgur Ozcelik, Selvihan Beysel
Keywords
Related Articles
- EP ID EP413535
- DOI 10.15226/2374-6890/5/4/001113
- Views 114
- Downloads 0
Clinical Variability in Familial X-Linked Hypohidrotic Ectodermal Dysplasia with 2q12Mutation: A Rare Case Report of Female Siblings Agony
Background: Hypohidrotic Ectodermal dysplasia (HED) is a hereditary entity characterized by the abnormal development of embryonic ectodermally derived organs including sweat glands, teeth, and hair. The most prevalent fo...
Pentraxin 3 as A Cardiovascular Marker in Primary Hyperparathyroidism
Aim: Pentraxin 3 (PTX3) is an acute-phase glycoprotein, which is increased in patients with cardiovascular disease (CVD) and considered as a predictor of CVD in the general population. Accumulating evidence suggests that...
Dyslipidemia in Subclinical Hypothyroidism: A Case-Control Study
Subclinical hypothyroidism (SCH) affects 7.5-8.5% of women and 2.8-4.4% of men. Overt hypothyroidism is characterized by dyslipidemia, however controversy persists regarding the lipids level in SCH and its clinical signi...
SGLT-2i and Cardiovascular Outcomes: A Meta-Analysis of The Asian Cohort
Sir, Recent diabetes guidelines have upgraded the position of sodium glucose cotransporter 2 inhibitors (SGLT-2i) based on the publication of cardiovascular outcomes trials (CVOT). However, divergent signals have emerged...
No Effect of Aprotinin (Trasylol™) on Degradation of Exogenous and Endogenous Glucagon in Human, Mouse and Rat Plasma
Traditionally, aprotinin (Trasylol™) has been added to plasma samples prior to glucagon analysis. However, the evidence for the need of aprotinin is sparse and based on results obtained when radioimmunoassay (RIA) techni...